Atorolimumab
From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | RhD |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
 N Y (what is this?) (verify) | |
Atorolimumab is an immunosuppressive drug directed against the Rhesus factor.[1][2]
- ↑ WHO Drug Information
- ↑ Pelletier JP, Mukhtar F (2020). "Chapter 16 - Passive Monoclonal and Polyclonal Antibody Therapies". In Maitta RW (ed.). Immunologic Concepts in Transfusion Medicine. Philadelphia: Elsevier. p. 267. doi:10.1016/B978-0-323-67509-3.00016-0. ISBN 978-0-323-67510-9. S2CID 213508934.
| Intracellular (initiation) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |